Clinical trial · Interventional
Pilot Study Of Unrelated UCB Transplant for Non-Malignant Hematologic Conditions
A Pilot Study of Unrelated Umbilical Cord Blood Transplantation in Patients With Severe Aplastic Anemia, Inborn Errors in Metabolism, or Inherited Hematologic Stem Cell Disorders
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
RATIONALE: Umbilical cord blood transplantation may allow doctors to give higher doses of chemotherapy or radiation therapy and kill more cancer cells. PURPOSE: This phase II trial is studying how well umbilical cord blood transplantation works in treating patients with severe aplastic anemia, malignant thymoma, or myelodysplasia.
Conditions
Conditions (3)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Leukemia | Leukemia | ONTOLOGY_EXACT | 0.90 |
| Myelodysplastic/Myeloproliferative Diseases | Myelodysplastic/Myeloproliferative Neoplasm | ALIAS | 0.90 |
| Myelodysplastic Syndromes | Myelodysplastic Syndrome | ALIAS | 0.90 |
Interventions
Interventions (8)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| anti-thymocyte globulin | Biological | — | UNRESOLVED |
| bone marrow ablation with stem cell support | Procedure | — | UNRESOLVED |
| busulfan | Drug | Busulfan | ALIAS |
| cyclophosphamide | Drug | Cyclophosphamide | ALIAS |
| melphalan | Drug | Melphalan | ALIAS |
| methylprednisolone | Drug | — | UNRESOLVED |
| radiation therapy | Radiation | — | UNRESOLVED |
| umbilical cord blood transplantation | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- Event-free survival by disease assessment
- timeFrame
- at 100 days and at 6, 9, 12, 18, and 24 months
Secondary outcomes (1)
- measure
- Umbilical cord blood donor engraftment by chimerism and complete blood count (CBC) at time of myeloid recovery.
- timeFrame
- 100 days and at 6, 9, 12, 18, and 24 months
Eligibility
Eligibility (as posted)
- Sex
- All
- Maximum age
- 55 Years
Show eligibility criteria text
DISEASE CHARACTERISTICS: * Histologically confirmed diagnosis of severe aplastic anemia based on bone marrow cellularity of less than 20% * Must meet at least two of the following criteria: * Granulocyte count less than 500/mm\^3 * Platelet count less than 20,000/mm\^3 * Reticulocyte count less than 50,000/mm\^3 * Following etiologies eligible: * Fanconi's anemia * Hypoplastic leukemia * Monosomy 7 * Drug exposure (chloramphenicol, NSAIDS) * Viral exposure (EBV, hepatitis, parvovirus, HIV) * Nutritional deficiencies * Thymoma * Paroxysmal nocturnal hemoglobinuria * Amegakaryocytic thrombocytopenia OR * Histologically confirmed myelodysplastic syndrome (MDS) that is refractory to medical management or with cytogenic abnormalities predictive of transformation into acute leukemia, including 5q-, 7q-, monosomy 7, or trisomy 8 * The following etiologies only are eligible: * Refractory anemia * Refractory anemia with ringed sideroblasts * De novo primary MDS * Therapy-related secondary MDS OR * Confirmed diagnosis of inherited hematopoietic disorder that is refractory to medical management * Following etiologies eligible: * Severe combined immunodeficiency * Familial erythrophagocytic lymphohistiocytosis * Wiskott-Aldrich syndrome * Kostmann's syndrome (infantile histiocytosis) * Chronic granulomatous disease * Leukocytic adhesion deficiency * Chediak-Higashi syndrome * Paroxysmal nocturnal hemoglobinuria * Fanconi's anemia * Dyskeratosis congenita * Diamond-Blackfan anemia * Amegakaryocytic thrombocytopenia * Osteopetrosis * Gaucher's disease * Lesch-Nyhan syndrome * Mucopolysaccharidoses * Lipodoses * Autologous or haploidentical related peripheral blood stem cells available as backup * Serologically matched umbilical cord blood unit available in the New York Blood Center's Placental Blood Project, or other acceptable umbilical cord blood registry PATIENT CHARACTERISTICS: Age: * 55 and under Performance status: * Zubrod 0-1 * Karnofsky 80-100% Life expectancy: * At least 3 months Hematopoietic: * See Disease Characteristics Hepatic: * ALT/AST no greater than 4 times normal * Bilirubin no greater than 2.0 mg/dL Renal: * Creatinine no greater than 2.0 mg/dL * Creatinine clearance at least 50 mL/min Cardiovascular: * Normal cardiac function by echocardiogram or radionuclide scan * Shortening fraction or ejection fraction at least 80% normal for age * Non-Fanconi patients with acquired or congenital cardiomyopathy may receive melphalan as a substitute for cyclophosphamide Pulmonary: * FVC and FEV\_1 at least 60% of predicted for age * DLCO at least 60% of predicted in adult patients Other: * No active concurrent malignancy * No active infection * Not pregnant or nursing * HIV negative * Must have an available serologic matched Umbilical Cord Blood Unit (UCBU) in the New York Blood Center's Placental Blood Project, or other acceptable Umbilical Cord Blood (UCB) registry PRIOR CONCURRENT THERAPY: Biologic therapy: * Not specified Chemotherapy: * No concurrent cytotoxic chemotherapy Endocrine therapy: * No concurrent immunosuppressive medications Radiotherapy: * No concurrent radiotherapy Surgery: * Not specified
References
Publications (1)
- BACKGROUNDLaughlin MJ, Barker J, Bambach B, Koc ON, Rizzieri DA, Wagner JE, Gerson SL, Lazarus HM, Cairo M, Stevens CE, Rubinstein P, Kurtzberg J. Hematopoietic engraftment and survival in adult recipients of umbilical-cord blood from unrelated donors. N Engl J Med. 2001 Jun 14;344(24):1815-22. doi: 10.1056/NEJM200106143442402. PMID 11407342